The goal of this observational study was to evaluate trends and determinants of SGLT2 inhibitor (SGLT2i) prescriptions in heart failure patients from 2021 to 2024, particularly in relation to LVEF subgroups and evolving scientific evidence (EMPEROR-Preserved, DELIVER, 2023 Guidelines). Participant population were adults with heart failure using the Satelia®Cardio web application to remotely monitor their condition. The main questions it aims to answer are: * to compare the prescription of treatments (including doses, and distribution of patients according to various therapeutic classes recommend for heart failure) with ESC recommendations to see to what extent GDMTs are adhered to. * to quantify the association between the presence of treatments and the risk of alerts/hospitalizations and overall death and as a function of LVEF using telemonitoring. * to evaluate the adherence across patient profiles and cardiologist practices (outpatient vs. hospital-based). Participants will complete follow-up, quality-of-life and patient support questionnaires and provide data regarding their treatments on the web application.
A retrospective, multicenter descriptive study was conducted in France from January 1, 2021 to December 31, 2024. The REMOTE-HF study included 17,551 patients enrolled in remote monitoring program for heart failure (HF) management. We described and analyzed the implementation of ESC guidelines in patients monitored remotely with a web application named Satelia®Cardio (NP Medical). Key clinical parameters such as age, gender, NYHA class, LVEF, and HF etiology were analyzed. Prescribed therapies including ACEi/ARB/ARNis, beta-blockers, MRAs, and SGLT2 inhibitors, were compared against the European Society of Cardiology (ESC) guideline-directed medical therapies (GDMTs). Adherence was evaluated across patient profiles and cardiologist practices (outpatient vs. hospital-based) in France.
Study Type
OBSERVATIONAL
Enrollment
17,551
Medical Affairs Department, NP Medical
Bordeaux, France
To evaluate trends and determinants of SGLT2 inhibitor (SGLT2i) prescriptions in heart failure patients.
Time frame: From January 2021 to December 2024.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.